Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Aktievalen: Aktiespararnas korta portfölj – 20 aktier som ska slå index

Analyser av Neola Medical

Kurs från TradingView
Visa mer ▼
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Neola Medical (Q2 Review): Funding secured, focus shifts to 2027 studies - Redeye

Redeye provides an update following Neola Medical’s Q2 2026 report.

Redeye • 21 aug 07:10

Neola medical: Funded to continue clinical validation - Redeye

Redeye interviewed Neola Medical's CEO, Hanna Sjöström, following the company's Q2 2026 report.

Redeye • 21 aug 07:08

Neola Medical: Rights issue outcome - Redeye

Redeye comments on Neola Medical’s rights issue outcome and updates our model accordingly, resulting in a slight adjustment to our fair valu...

Redeye • 22 jun 10:30

Neola Medical (Q1 Review): An undramatic report after an eventful period - Redeye

Redeye provides an update following Neola Medical’s Q1 2026 report.

Redeye • 20 maj 07:06

Neola Medical: Rights issue announcement - Redeye

Redeye comments on Neola Medical’s rights issue. We view the announcement as expected, and as we had already incorporated a capital raise in...

Redeye • 28 apr 10:31

Neola Medical: Update on Swedish clinical study data - Redeye

Redeye comments on Neola Medical’s update regarding the analysis of the Swedish clinical study.

Redeye • 21 apr 13:46

Neola Medical (Q4 Review): Eyes on upcoming clinical data - Redeye

Redeye provides an update following Neola Medical’s Q4 2025 report.

Redeye • 13 feb 07:28

Neola Medical (Q3 Review): Revised timeline - Redeye

Redeye provides an update following Neola Medical’s Q3 2025 report.

Redeye • 06 nov 2025 07:36

Neola Medical Q2: Potential share price trigger incoming - Redeye

Redeye provides an update following Neola Medical’s Q2 2025 report.

Redeye • 26 aug 2025 07:24

Neola Medical: US hospital agreement - Redeye

Redeye is positive about Neola Medical’s agreement with Children’s Regional Hospital in New Jersey, which enables the initiation of the pivo...

Redeye • 11 jun 2025 09:03

Neola Medical: Directed issue - Redeye

Redeye comments on Neola Medical’s directed issue, raising approximately SEK20m.

Redeye • 13 mar 2025 07:20

Neola Medical Q4: Vital clinical data incoming - Redeye

Redeye provides an update following Neola Medical’s Q4 2024 report.

Redeye • 13 feb 2025 07:19

Neola Medical: Approved clinical study in Sweden - Redeye

Redeye comments on Neola Medical’s approved clinical study in Sweden, which is expected to run for approximately four months and serve as a ...

Redeye • 11 feb 2025 11:45

Neola Medical Q3: Entering the clinical validation phase - Redeye

Redeye provides an update following Neola Medical’s Q3 2024 report.

Redeye • 07 nov 2024 10:28

Neola Medical: Meeting an unmet need in neonatal care - Redeye

Redeye initiates coverage of Neola Medical, a Swedish medtech company specialising in neonatal intensive care.

Redeye • 24 okt 2024 11:48

GPX Medical: Momentum in Clinical and Regulatory Activities Continues - Analyst Group

1.1 million infants die annually, where 80% suffer from Respiratory Distress Syndrome (RDS).

Analyst Group • 27 maj 2022 09:39

Analyst Group kommenterar GPX Medicals Q1-rapport

GPX Medical publicerade idag den 19 maj bolagets kvartalsrapport för Q1-22.

Analyst Group • 20 maj 2022 07:49

Analyst Group kommenterar GPX Medicals Q1-rapport

GPX Medical publicerade idag den 19 maj bolagets kvartalsrapport för Q1-22.

Analyst Group • 19 maj 2022 16:53

Analyst Group kommenterar GPX Medicals positiva studieresultat

Idag tillkännagav GPX Medical att den kliniska forskaren och neonatologen Jurate Panaviene presenterar resultat och slutsatser från de först...

Analyst Group • 25 apr 2022 15:35

Analyst Group kommenterar GPX Medicals Q4-rapport

GPX Medical publicerade idag den 15 februari sin bokslutskommuniké för år 2021.

Analyst Group • 15 feb 2022 14:53

GPX Medical: Continuous Lung Monitoring for Infants in need - Analyst Group

1.1 million infants die annually, where 80% suffer from Respiratory Distress Syndrome (RDS).

Analyst Group • 31 jan 2022 13:28

GPX Medical: Har vind i seglet - Analyst Group

Försäljningen till University College Cork av ett första NEOLA®-system är mycket värdefullt ur ett strategiskt perspektiv då det bidrar till...

Analyst Group • 25 aug 2021 11:32

GPX Medical: Analyst Group kommenterar GPX Medicals Q2-rapport - Analyst Group

GPX Medical publicerade igår den 17 augusti sin delårsrapport för årets andra kvartal.

Analyst Group • 19 aug 2021 08:49